A NOVEL ANTI-ESTROGEN RECEPTOR TARGETED WATER-SOLUBLE QDs FOR BREAST CANCER CELL IMMUNOFLUORESCENT LABELING

This research is aimed to develop a novel kind of biomarker based on water-soluble quantum dots (QDs) conjugated with estrogen receptor (ER) for the detection of breast cancer (BC). To achieve the purpose, hydrophobic octadecylamine-coated QDs were encapsulated with amphiphilic biocompatible centipede-like polymer p(aspartate)- Na -graft-p(ethylene glycol)-dodecylamine (PASP- Na -g-PEG-DDA), and then modified with ER monoclonal antibodies, which is one of the most popular biomarkers for the detection and management of breast cancer worldwide. The targeted QDs kept the original optical property of QDs. The cytotoxicity in vitro experiments showed that QDs-ER probes had no obvious toxic side effects. Remarkably, confocal laser scanning microscopy (CLSM) revealed that the localized fluorescence appeared around the nucleus of human breast cancer cell MCF7 (ER positive) compared with that of human breast cancer cell MBA-MD-231 (ER negative). According to the above analysis, this new kind of probe has great potential in the diagnosis of breast tumor in vitro in future clinical application.

Download Full-text

ChIP-seq predicted estrogen receptor biding sites in human breast cancer cell line MCF7

Tumor Biology ◽

10.1007/s13277-014-1627-4 ◽

2014 ◽

Vol 35 (5) ◽

pp. 4779-4784 ◽

Cited By ~ 4

Author(s):

Qi Li ◽

Huichun Wang ◽

Leyang Yu ◽

Jun Zhou ◽

Jingde Chen ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Cell Line ◽

Cancer Cell ◽

Breast Cancer Cell ◽

Breast Cancer Cell Line ◽

Human Breast Cancer ◽

Cancer Cell Line ◽

Human Breast Cancer Cell ◽

Human Breast

Download Full-text

A novel therapeutic strategy for ER-negative human breast cancers, targeting AP-1 activity

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.14129 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 14129-14129

Author(s):

K. Sakaguchi ◽

H. Nakajima ◽

I. Fujiwara ◽

N. Mizuta ◽

J. Magae

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Cell Lines ◽

Cancer Cell ◽

Breast Cancer Cell ◽

Human Breast Cancer ◽

Human Breast Cancer Cell ◽

Breast Cancers ◽

Human Breast ◽

Er Positive

14129 Background: While agents targeting estrogen receptors are the most effective in adjuvant therapy for human breast cancers expressing estrogen receptor(ER), breast cancers lacking ER are clinically serious, because they are highly malignant and exhibit resistance to the usual anti-cancer drugs, including estrogen receptor-antagonists and DNA breaking agents. Although a transcription factor, AP-1, is known to be related to tumor malignancy including metastasis, invasion and drug-resistance, it remains to be elucidated how AP-1 plays in development and expression of malignant characters of human breast cancers. Methods and Results: Here, we used MX-1, a human breast cancer cell line lacking ER and several ER positive cell lines, to clarify the roles of AP-1 and the therapeutic efficacy of ascochlorin, a newly developed prenylphenol antibiotic on ER-negative breast cancer. We found that MX-1 exhibited higher AP-1 activity and expressed higher levels of c-Jun, c-Fos and Fra-1 when compared with conventional ER-positive human breast cancer cell lines. Consistent with this study in vitro, histological study on human breast cancer tissues suggests that ER-negative cancers express high Fra-1 protein, and that paclitaxel- sensitive cancers express low Fra-1 protein. The ascochlorin, which inhibits AP-1 through the Erk signaling pathway, suppressed the AP-1 activity of MX-1 cells, and selectively killed MX-1 cells, partly due to induction of apoptosis. Moreover, administration of ascochlorin elongated life span of mice intraperitoneally implanted with murine mammary carcinoma cells. Conclusions: Our results suggest that AP-1 is an effective clinical target molecule for the treatment of ER-negative human breast cancer, and that ascochlorin is promising therapeutic agent for these refractory breast cancers. No significant financial relationships to disclose.

Download Full-text